---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023482"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:38:37.870881+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Q1 2025 net loss $51.9M; cash $158.3M; pipeline on track for CGD data in 2025

## Summary
- Net loss $51.9M (vs $45.8M Q1 2024); R&D $40.6M, G&A $13.3M.
- Cash, equivalents, investments $158.3M as of March 31, 2025, down from $204.5M at Dec 31, 2024.
- Initial Phase 1/2 data for PM359 (p47 phox CGD) expected in 2025.
- IND/CTA for PM577 (Wilson's Disease) on track for 1H 2026; AATD program unveiled with IND/CTA mid-2026.

## SEC filing metadata
- accession: 0001628280-25-023482
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828025023482/0001628280-25-023482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828025023482/prme-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023482
- JSON: https://secwatch.observer/filing/0001628280-25-023482.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.